Financial Results, Launches, Adjusted Conversion Rates, Upcoming Presentations, and Stock Movements - Analyst Notes on AbbVie, Chemed, Antares Pharma, Magellan Health Services, and Natus Medical

NEW YORK, April 3, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Chemed Corp. (NYSE: CHE), Antares Pharma Inc. (NASDAQ: ATRS), Magellan Health Services Inc. (NASDAQ: MGLN), and Natus Medical Inc. (NASDAQ: BABY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

AbbVie Inc. Analyst Notes 

On March 24, 2014, AbbVie Inc. (AbbVie) reported that it will present new data from its Phase III Hepatitis C Development Program at the 2014 International Liver Congress™ (ILC) from April 9, 2014 to April 13, 2014 in London. The Company stated that detailed results from SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will also be presented at the ILC from April 10, 2014 to April 12, 2014. AbbVie informed that these four studies are from its phase III clinical trial program, the largest phase III program of an investigational, all-oral, interferon-free regimen for the treatment of chronic hepatitis C virus (HCV) infection in genotype 1 (GT1) adult patients. The Company added that it will present additional data during the presentations throughout the Congress. The full analyst notes on AbbVie Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/ABBV/report.pdf

--

Chemed Corp. Analyst Notes 

On March 18, 2014, Chemed Corp. (Chemed) announced that the conversion rate on its 1.875% Convertible Senior Notes due May 15, 2014 has been adjusted to c. 12.8 shares of Chemed's capital stock per $1,000 principal amount of the notes. According to Chemed, the adjusted conversion rate is equivalent to an adjusted conversion price of approximately $78.37 per share. The Company stated that the notes will mature on May 15, 2014, and are convertible in accordance with their terms before the business closes on May 12, 2014. Additionally, the Company stated that for all conversions before maturity, the consideration payable upon conversion will be based on the volume-weighted average price of its capital stock over a 40 trading day measurement period, which began on March 17, 2014, and is expected to end on May 12, 2014. The full analyst notes on Chemed Corp. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/CHE/report.pdf

--

Antares Pharma Inc. Analyst Notes 

On March 13, 2014, Antares Pharma Inc. (Antares Pharma) reported its Q4 2013 and full-year 2013 financial results. Q4 2013 total revenue went down by 13.7% YoY to $4.7 million, while full-year total revenue declined by 8.7% YoY to $20.6 million. Q4 2013 net loss was $5.6 million or $0.04 per diluted share, compared to Q4 2012 net loss of $5.0 million or $0.04 per diluted share in Q4 2012. Full-year 2013 net loss came in at $20.5 million or $0.16 per diluted share, compared to full-year 2012 net loss of $11.4 million or $0.10 per diluted share in full year 2012. Paul K. Wotton, Ph.D., President and CEO of Antares Pharma, commented, "The October approval and subsequent first quarter launch of OTREXUP to rheumatologists and dermatologists capped an incredibly successful year for our Company and our shareholders. We believe the coming year will bring continued success on the commercial front as well as on the development front as our QuickShot testosterone product enters the next phase of studies toward an expected 2015 filing of a New Drug Application, and we will expand our pipeline to create additional long-term shareholder value." The full analyst notes on Antares Pharma Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/ATRS/report.pdf

--

Magellan Health Services Inc. Analyst Notes 

On March 20, 2014, Magellan Health Services Inc. (Magellan Health Services) reported that its division, Magellan Rx Management, announced the launch of MRxAudit - a comprehensive tool to help determine the effectiveness of pharmacy benefit management (PBM) services. The Company added that the tool is being offered on a complimentary basis for a limited time to help groups gauge the effectiveness of their current PBM. Commenting on the launch, Matthew Mertel, Senior Vice President of Product and Market at Magellan Rx Management, stated, "MRxAudit is an easy-to-use tool that evaluates current pharmacy benefit performance and benchmarks this data against industry averages. We believe strongly that the information this tool provides is critical to help identify areas of potential improvement and accountability, which is why we're providing it on a complimentary basis for a limited time." The full analyst notes on Magellan Health Services Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/MGLN/report.pdf

--

Natus Medical Inc. Analyst Notes 

On March 31, 2014, Natus Medical Inc.'s (Natus Medical) stock went up by 5.31%, to close at $25.80. For the past five-day trading period, the Company's stock increased 3.77%, compared to the Nasdaq Composite which went down by 0.65% during the same trading period. The full analyst notes on Natus Medical Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/BABY/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review